Kabbany MN, Conjeevaram Selvakumar PK, Watt K, et al. Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of national health and nutrition examination survey data. Am J Gastroenterol. 2017;112:581–7.
Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–33.
Article CAS PubMed Google Scholar
Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021;398:1359–76.
Pais R, Charlotte F, Fedchuk L, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550–6.
Article CAS PubMed Google Scholar
Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Netw Open. 2019;2:e1912565.
Article PubMed PubMed Central Google Scholar
Teh SH, Nagorney DM, Stevens SR, et al. Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology. 2007;132:1261–9.
Berzigotti A, Garcia-Tsao G, Bosch J, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555–61.
Yin Y, Li Y, Shao L, et al. Effect of body mass index on the prognosis of liver cirrhosis. Front Nutr. 2021;8:700132.
Article PubMed PubMed Central Google Scholar
Berzigotti A, Albillos A, Villanueva C, et al. Lifestyle intervention by a 16-week programme of supervised diet and physical exercise ameliorates portal hypertension in patients with cirrhosis and obesity- the SportDiet study. Hepatology. 2014;60:253A.
Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397:293–304.
Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401:1786–97.
Pais R, Aron-Wisnewsky J, Bedossa P, et al. Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. Hepatology. 2019;70:44A.
Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA: J Am Med Assoc. 2021;326:2031–42.
Mallet M, Silaghi CA, Sultanik P, et al. Current challenges and future perspectives in treating patients with NAFLD-related cirrhosis. Hepatology. 2023. https://doi.org/10.1097/HEP.0000000000000456.
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28:528–62.
Bischoff SC, Barazzoni R, Busetto L, et al. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline. Clin Nutr. 2022;41:2364–405.
Diwan TS, Lee TC, Nagai S, et al. Obesity, transplantation, and bariatric surgery: an evolving solution for a growing epidemic. Am J Transplant. 2020;20:2143–55.
Dallal RM, Mattar SG, Lord JL, et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes Surg. 2004;14:47–53.
Patton H, Heimbach J, McCullough A. AGA clinical practice update on bariatric surgery in cirrhosis: expert review. Clin Gastroenterol Hepatol. 2021;19:436–45.
Rebibo L, Gerin O, Verhaeghe P, et al. Laparoscopic sleeve gastrectomy in patients with NASH-related cirrhosis: a case-matched study. Surg Obes Relat Dis. 2014;10:405–10.
Pestana L, Swain J, Dierkhising R, et al. Bariatric surgery in patients with cirrhosis with and without portal hypertension: a single-center experience. Mayo Clin Proc Mayo Clin. 2015;90:209–15.
Mumtaz K, Lipshultz H, Jalil S, et al. Bariatric surgery in patients with cirrhosis: careful patient and surgery-type selection is key to improving outcomes. Obes Surg. 2020;30:3444–52.
Northup PG, Wanamaker RC, Lee VD, et al. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg. 2005;242:244–51.
Article PubMed PubMed Central Google Scholar
Mahmud N, Kaplan DE, Taddei TH, et al. Frailty is a risk factor for postoperative mortality in patients with cirrhosis undergoing diverse major surgeries. Liver Transpl. 2021;27:699–710.
Article PubMed PubMed Central Google Scholar
Hanipah ZN, Punchai S, McCullough A, et al. Bariatric surgery in patients with cirrhosis and portal hypertension. Obes Surg. 2018;28:3431–8.
Manzano-Nunez R, Rivera-Esteban J, Comas M, et al. Outcomes of patients with severe obesity and cirrhosis with portal hypertension undergoing bariatric surgery: a systematic review. Obes Surg. 2023;33:224–33.
Mahmud N, Fricker Z, Hubbard RA, et al. Risk prediction models for post-operative mortality in patients with cirrhosis. Hepatology. 2021;73:204–18.
Nguyen GC, Correia AJ, Thuluvath PJ. The impact of cirrhosis and portal hypertension on mortality following colorectal surgery: a nationwide, population-based study. Dis Colon Rectum. 2009;52:1367–74.
Reverter E, Cirera I, Albillos A, et al. The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. J Hepatol. 2019;71:942–50.
Fares N, Robic MA, Péron JM, et al. Transjugular intrahepatic portosystemic shunt placement before abdominal intervention in cirrhotic patients with portal hypertension: lessons from a pilot study. Eur J oGastroenterol Hepatol. 2018;30:21–6.
Schlenker C, Johnson S, Trotter JF. Preoperative transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic patients undergoing abdominal and pelvic surgeries. Surg Endosc. 2009;23:1594–8.
Aryan M, McPhail J, Ravi S, et al. Perioperative transjugular intrahepatic portosystemic shunt is associated with decreased postoperative complications in decompensated cirrhotics undergoing abdominal surgery. Am Surg. 2022;88:1613–20.
Tabchouri N, Barbier L, Menahem B, et al. Original study: transjugular intrahepatic portosystemic shunt as a bridge to abdominal surgery in cirrhotic patients. J Gastrointest Surg. 2019;23:2383–90.
Article CAS PubMed Google Scholar
Patel P, Irani M, Graviss EA, et al. Impact of pre-operative transjugular intrahepatic portosystemic shunt on post-operative outcomes following non-transplant surgeries in patients with decompensated cirrhosis. Transl Gastroenterol Hepatol. 2023;8:9.
Article PubMed PubMed Central Google Scholar
Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(1426–1437):1437.e1421-1429.
Jalan R, Saliba F, Pavesi M, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61:1038–47.
Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery. Obes Surg. 2023;33:3–14.
留言 (0)